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Abstract 
Ethnopharmacological relevance 
Uncaria tomentosa (Willdenow ex Roemer & Schultes) DC. (Rubiaceae) is a Peruvian thorny 
liana, commonly known as “cat's claw”, and traditionally used in folk medicine to deal with 
several inflammatory diseases. Mitraphylline (MTP) is the most abundant pentacyclic 
oxindolic alkaloid (POA) from U.Tomentosa and has been reported to modify the 
inflammatory response. Herein, we have sought to identify the mechanisms underlying this 
modulatory effect of MTP on primary human monocytes and its ability to regulate 
differentiation processes on human primary monocyte and monocyte-derived macrophages.   
 
Material and methods  
In vitro studies with human primary monocytes and monocyte-derived macrophages were 
performed. Monocytes and M0 macrophages were exposed to MTP (25 µM) and LPS (100 
ng/mL). M0 macrophages were polarized to M1 and M2 phenotypes in the absence or 
presence of MTP. The activation state of monocytes/macrophages was assessed by flow 
cytometry, gene expression and protein analysis of different specific markers. 
 
Results 
In human primary monocytes, the incubation of MTP for 24 h reduced the number of classical 
(CD14++CD16-) and intermediated (CD14++CD16+) subsets when compared to untreated or 
LPS-treated cells. MTP also reduced the chemotactic capacity of human primary monocytes. 
In addition, MTP promoted the polarization of M0 macrophages toward an anti-inflammatory 
M2 phenotype, the abrogation of the release of pro-inflammatory cytokines such as TNFα, IL-
6 or IL-1β, as well as the restoration of markers for M2 macrophages in LPS-treated M1 
macrophages.  
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Conclusions 
Our results suggest that MTP may be a key modulator for regulating the plasticity of 
monocytes/macrophages and the attenuation of the inflammatory response. 
 
Chemical compounds studied in this article Mitraphylline (Pubchem CID: 94160) 
 
KEYWORDS Uncaria tomentosa mitraphylline, monocytes, macrophages, polarization and 
inflammatory diseases.  
 
ABBREVIATIONS MTP: mitraphylline, POA: pentacyclic oxindolic alkaloid, U. 
tomentosa: Uncaria tomentosa, LPS: lipopolysaccharide, TNFα:  Tumor Necrosis Factor 
Alpha, IL: Interleukin, IFNγ: Interferon gamma, CCR2: chemokine (C-C motif) receptor 2, 
CCL2: Chemokine (C-C motif) ligand 2, MCSF: Macrophage colony-stimulating factor. 
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1. Introduction  
Uncaria tomentosa (Willdenow ex Roemer and Schultes) DC and its relative Uncaria 
guanensis (Aublet) Gmell. (Rubiaceae) are plants widely used in folk and complementary 
medicine under the names of “Cat’s claw”. Uncarias are vines naturally growing in Peru and 
some other countries of South and Central America, and have there numerous applications in 
both human and animal medicine. U. tomentosa has been previously reported to deal with 
several inflammatory diseases (Müller et al., 2011; Rosenbaum et al., 2011), modulating the 
immune system and antitumor activities (Garcia-Gimenez., et al 2010; Rojas-Duran et al., 
2012; Dietrich et al., 2014). Owing to the systematically growing applications of U. 
tomentosa in therapy, it is important to better recognize its pharmacological properties and 
safety of using. 
Cat’s claw contains more than 50 chemical constituents, including oxindole and indole 
alkaloids, polyphenols, among others (Heitzman et al., 2005). The majority alkaloids of 
Uncaria are indole and oxindole families (Laus et al., 2004), which are well recognized as 
phytochemical markers of this species with relevant pharmacological activities (Heitzman et 
al., 2005). Mitraphylline (MTP) is an oxindole alkaloid and the most ubiquitous alkaloid 
being present in 20 of 34 Uncaria species (Heitzman et al., 2005). Most of pharmacological 
studies have been focused on the fractions of either a plant species or a “crude drug”, 
considered as a preparation from either a single or a mixture of Uncaria plants. However, 
fewer studies, if any, have paid attention to the bioactivity of isolated compound(s) such as 
MTP. Our research team have previously reported the isolation of MTP from the dried inner 
bark of U. tomentosa, the elucidation of its structure by NMR spectroscopy analysis and its 
antitumor properties on human sarcoma and breast cancer cells (García-Prado et al., 2007). 
However, little is known on the potential of MTP to mitigate the inflammatory response. 
Monocytes are particularly involved in inflammatory processes (Shi et al., 2011). They are 
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classified into three subsets: classical CD14++CD16–, intermediate CD14++CD16+, and 
non-classical CD14+CD16++ monocytes (Ziegler-Heitbrock et al., 2010). So far, classical 
monocytes represent the major fraction, about 85% of total monocytes that highly express the 
migratory chemokine receptor CCR2 (Ingersoll et al., 2010; Wong et al., 2011). They are 
professional phagocytes giving rise to classical M1 macrophages, which generate reactive 
oxygen species and secrete cytokines (TNFα, IL-1β, IL-6) in response to LPS during infection 
or inflammation (Mossig et al., 2009; Wong et al., 2011; Zwada et al., 2011). Intermediate 
monocytes display highest levels of CCR5, TLR4, CD163, and HLA-DR during activation 
and also secrete pro-inflammatory cytokines (Wong et al., 2011; Shantsila et al., 2011). Non-
classical monocytes are less granular and smaller in size, with lower expression of CCR2 than 
classical or intermediate subsets (Cross et al., 2010; Wong et al., 2011; Shantsila et al., 2011). 
These monocytes rich in CD16 are functionally involved in tissue repairing, patrolling, wound 
healing, and have the tendency to be polarized into non-classically M2 macrophages with an 
anti-inflammatory phenotype in response to a variety of stimuli, including IL-4 (Benoit et al., 
2008; Gordon et al., 2010).  
In the present study, we further investigated whether MTP may act as an immune-modulator 
and anti-inflammatory effector on human primary monocytes and monocyte-derived 
macrophages. 
 
2. Material and methods 
2.1. Bark extract  
The plant material was collected in the Peruvian forest and was provided by Dr Carlos S 
González and was identified in the Botanic Department of the San Lorenzo Chemical Science 
School from the Asuncion University in Paraguay. The plant extract was obtained and the 
compound mitraphylline identified as previously described in (Garcia Prado et al., 2007). 
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Briefly, 500 g of Uncaria tomentosa dried inner bark were treated with ammonium hydroxide 
and extracted with 500 ml of dichloromethane for 3 times. After filtration, the obtained 
solution was concentrated in vacuo to afford a residue, which was dissolved in a hydrochloric 
acid solution (3%). Ammonium hydroxide and dichloromethane were added again. After 
concentration in vacuo, the purified alkaloid fraction was obtained as a brown residue and the 
yield was 0.1%. 
                                                                                                              
2.2. Isolation and identification of Mitraphylline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
The dried residue of alkaloid fraction (0.5 g) was subjected to a silica gel column 
chromatography, compacted with silica gel 0.063-0.2 mm (0.8x25 cm), followed by a 
gradient elution with various mixtures of n-hexane, dichloromethane, and methanol. Twenty-
five fractions of about 15 mL each were collected. 200 mg of white crystal (Mitraphylline) 
were obtained in the fractions 14-16 (eluted with CH2Cl2/MeOH) that corresponded to 87.2% 
of the total alkaloids.  EIMS and 1H and 13C NMR experiments were carried out for its 
identification using an AVANCE 500 spectrophotometer. The following 2D NMR 
experiments COSY-DQF, (1H-13C)-HSQC, (1H-13C)-HMBC, and NOESY correlation were 
used to elucidate its structure. Furthermore, the 15N chemical shift of the isomeric oxindole 
alkaloids, (1H-15N)-HMBC, was necessary to facilitate its characterization. The solvent used 
for NMR spectra was CDCl3 (Garcia Prado et al., 2007). 
 
2.3. Blood collection and monocyte isolation 
This study was conducted according to the guidelines of good clinical practice. Peripheral 
venous blood was isolated from healthy adult volunteers (< 35 years old) from the Hospital 
Virgen del Rocio at Seville. The investigation conformed to the principles outlined in the 
Helsinki Declaration of the World Medical Association. Donors declared that they were non-
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smokers and were not taking any medication. Blood samples were immediately collected into 
K3EDTA-containing Vacutainer tubes (Becton Dickinson, NJ, USA) and peripheral blood 
mononuclear cells (PBMCs) were isolated by centrifugation over Ficoll Histopaque gradient 
(Sigma-Aldrich Chem, MO, USA). Monocytes were then isolated from PBMCs using positive 
selection with CD14 MicroBeads according to the manufacturer’s instructions (MACS, 
Myltenyi Biotec, Madrid, Spain). Monocytes were tested for purity by CD14 fluorescein 
isothiocyanate labelling and fluorescence-activated cell sorter (FACS) analysis using a 
FACScanto II flow cytometer and FACSDiva software (Becton Dickinson Immunocytometry 
Systems, CA, USA) (Varela et al., 2011). Following isolation, the cells were suspended in a 
RPMI 1640 medium supplemented with L-glutamine, penicillin, streptomycin, and 1% heat-
inactivated FCS. The monocytes were used within 24 h after isolation for the experiments. 
 
2.4. Monocyte differentiation and polarization into M1 and M2 macrophages 
Monocytes were induced to differentiate for 6 days in the presence of recombinant human M-
CSF (25 ng/mL) to obtain M0 macrophages. These cells were then cultured in RPMI 1640 
supplemented with L-glutamine, penicillin, streptomycin, and 10% heat-inactivated FCS. For 
M1 and M2 polarization, M0 macrophages were exposed to LPS (100 ng/mL) plus IFNγ (20 
ng/mL) and to IL-4 (20 ng/mL), respectively, for additional 24 h. MTP (25 µM) was also 
added to the medium as indicated. 
 
2.5. Cell viability 
Monocytes and macrophages seeded in 96-well plates (1x105 cells/well) were incubated in the 
presence (or absence) of different MTP concentrations for 24 h. At the end of the exposure 
time, cell viability was analysed by Annexin V binding and using a FACScanto II flow 
cytometer with a CellQuest software (BD). 
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2.6. Nitrite and cytokine production 
Cells in 24-well plates were treated (or untreated) with MTP (25 µM), and 30 min later 
stimulated with LPS (100 ng/mL) for 24 h. The culture supernatants (100 µL) were 
transferred to a 96-well assay plate mixed with Griess reagent (Sigma-Aldrich Chem) and 
incubated for 15 min at room temperature. The amount of nitrite, as an index of NO 
generation (Csonka et al 2014), was determined by the absorbance at 540 nm in an ELISA 
reader (BioTek, Bad Friedrichshall, Germany). After the extrapolation from a standard curve 
with sodium nitrite, the results were expressed as the percentage of nitrite compared with that 
of cells treated with only LPS. Dexamethasone (1 µM, Sigma-Aldrich Chem) was used as 
positive control. 
The cytokines levels of IL-1β, IL-6, and TNFα, which were released into cell supernatants, 
were measured by ELISA, following the indications of the manufacturer (Diaclone). 
 
2.7. Immunostaining analysis by FACS 
Membrane surface expression of CD16 (PE anti-human CD16, Miltenyi Biotec), CD14 
(APC-Cy7 anti-human CD14, Miltenyi Biotec), and CCR2 (APC anti-human CCR2, BD) in 
monocytes was assessed by FACS. According to the manufacturer's instructions, 5x105 of 
purified monocytes, after in vitro stimulation with (or without) LPS (100 ng/mL), were 
incubated with the above antibodies in the dark, at room temperature for 15 min. Thereafter, 
cells were fixed and erythrocytes were lysed with a volume (20×) of FACS lysing solution 
(BD). Fluorescence intensity was measured in a FACSCanto II flow cytometer with a 
CellQuest software (BD). Results were analysed using the Win-List software package (Verity 
Software House, ME, USA). Mean fluorescence intensity (MFI) of 104 counted cells was 
measured in each sample. Monocytes were gated as forward scatterhigh (FSChigh)-side 
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scatterhigh (SSChigh) cells. Expression levels were presented as MFI corrected for nonspecific 
binding of isotype control antibodies. 
 
2.8. RNA isolation and qRT-PCR analysis 
Total RNA was extracted from cells by using Trisure Reagent (Bioline), as instructed by the 
manufacturer. RNA quality was assessed by A260/A280 ratio in a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific). RNA (1 µg) was subjected to reverse transcription 
(iScript, Bio-Rad, CA, USA) according to the manufacturers’ protocol. An amount of 20 ng 
of the resulting cDNA was used as a template for real-time PCR amplifications. The mRNA 
levels for specific genes were determined in a MX3000P system (Stratagene). For each PCR 
reaction, cDNA template was added to Brilliant SYBR green QPCR Supermix (Bio-Rad) 
containing the primer pairs for either gene or for glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and hypoxanthine phosphoribosyltransferase (β-actine) as housekeeping genes 
(Table 1). All amplification reactions were performed in triplicate and average threshold cycle 
(Ct) numbers of the triplicates were used to calculate the relative mRNA expression of 
candidate genes. The magnitude of change of mRNA expression for candidate genes was 
calculated by using the standard 2-(ΔΔCt) method. All data were normalized to endogenous 
reference (GAPDH and β-actine) gene content and expressed as percentage of controls. 
 
2.9. Immunoblotting detection 
Macrophages derived from primary monocytes (1×106 cells/mL) were treated (or untreated) 
with MTP (25 µM) and LPS (100 ng/mL) for 18 h. After incubation, cells were rinsed, 
scraped off, and collected in ice-cold PBS containing a cocktail of protease and phosphatase 
inhibitors and processed to isolate cytoplasmic proteins. Protein concentration was measured 
for each sample using a protein assay reagent (Bio-Rad) according to the Bradford´s method 
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and using γ-globulin as a standard (Bradford, 1976). Aliquots of supernatant containing equal 
amount of protein (20 µg) were separated on 10% acrylamide gel by SDS polyacrylamide gel 
electrophoresis. In the next step, the proteins were electrophoretically transferred into a 
nitrocellulose membrane and incubated with specific primary antibodies, polyclonal mouse 
anti-human TNFα and IL1-β (Abcam, London, UK) and monoclonal mouse anti-human b-
actin (Sigma, Milan, Italy), overnight at 4 ºC. After rinsing, the membranes were incubated 
with a horseradish peroxidase-labelled (HRP) secondary antibody anti-rabbit (Cayman 
Chemical, MI, USA) (1:50000) or anti-mouse (Dako, GA, USA) (1:2000) containing 
blocking solution for 1-2 h at room temperature. To prove equal loading, the blots were 
analysed for β-actin expression using an anti-β-actin antibody (Sigma Aldrich Chem). 
Immunodetection was performed using enhanced chemiluminescence light-detecting kit 
(Pierce, IL, USA). The immunosignals were captured using a LAS-3000 Imaging System 
from Fujifilm Image Reader (Stamford, USA). Following normalization to the housekeeping 
loading control, the signals were analysed and quantified by an Image Processing and 
Analysis in Java (Image J, Softonic). 
 
2.10. Wound healing assay 
M0/M1 macrophages were plated in a 24-well tissue culture plate in complete growth 
medium to attain ~80% confluence. Cells were allowed to adhere for 24 h and then a line was 
scraped with a P-1000 micropipette tip. Non-adherent cells were aspirated away, and 
complete growth media was replaced. Macrophages were then incubated with MTP in the 
presence (or absence) of 10 nM recombinant human MCP-1 (PeproTech EC, London, UK). 
Serial images were taken at designated time points at ×100 magnification with Image J 
software, a standardized grid was placed over the images across the breadth of the denuded 
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zone, and cells migrating into this zone were counted in a blinded fashion. Each quantified 
sample represents counts from four different wells with two serial images taken per well. 
 
2.11. Data analysis 
All values in the figures and text are expressed as arithmetic means ± standard error (SEM). 
Data were evaluated with Graph Pad Prism Version 5.01 software (CA, USA). The statistical 
significance of any difference in each parameter among the groups was evaluated by one-way 
analysis of variance (ANOVA) following Dunnett’s multiple comparisons test as post hoc 
test. P values less than 0.05 were considered statistically significant. 
 
3. Results 
3.1. MTP upsetting the balance of primary monocyte subsets 
Monocytes were analysed for cell viability and different subset markers after 24 h of 
incubation with MTP (25 µM). Contrarily to staurosporine (1 µM) that was used as a positive 
control of cell death and caused spontaneous apoptosis (>52%) and necrosis (>19%), MTP 
did not induce any significant loss of viability in monocytes (Fig. 1A). Next, we measured 
surface expression of phenotypic markers (CD14 and CD16) to distinguish between classical, 
intermediate, and non-classical monocyte subsets. To approach this, primary monocytes were 
exposed to LPS (100 ng/mL) alone or in the presence of MTP. Compared to control untreated 
cells, LPS significantly increased the expression of CD14 in the classical and intermediate 
monocyte subsets (Fig. 1B). MTP did not only abrogate this LPS-related effect by decreasing 
the expression of CD14, but also by significantly increasing the expression of CD16 and 
thereby of non-classical monocyte subsets. In addition, MTP significantly decreased CCR2 
expression in the classical monocyte subset (Fig. 1C). 
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3.2 MTP shifts M1 to M2 macrophage phenotype 
Monocytes were cultured for 6 days with human recombinant M-CSF (25 ng/mL) to mature 
into M0 macrophages. The FACS analysis showed that 97% of M0 cells were positive for the 
macrophage marker CD68 (Fig. 2A). These cells were then treated with IFNγ (20 ng/mL) or 
IL-4 (20 ng/mL) for 24 h to generate M1 or M2 macrophages, respectively. Gene expression 
of phenotypic markers for M1 (CD64, CD80, and CD163) and M2 (CD200r and MR) 
macrophages was examined. As expected, CD64, CD80, and CD163 were upregulated by 
LPS plus IFNγ in M1 macrophages (Fig. 2B-D), whereas CD200r and MR were upregulated 
by IL-4 in M2 macrophages (Fig. 2E-F). The presence of MTP during the treatment of M0 
macrophages with IFNγ prevented the expression of M1 markers, reaching comparable levels 
to those found in M2 macrophages, and increased M2 markers. 
Based on active aerobic glycolytic program in M1 macrophages that results in high 
production of nitrite oxides (NO2-) (Galván-Peña et al., 2014), we tested the influence of 
MTP on NO2- production in M0 macrophages treated with IFNγ. It was interesting to note 
that MTP completely abolished to normalize NO levels in these cells (Fig. 2G).  
 
3.3. MTP restricts CCR2-dependent migration 
Classically activated M1 macrophages are recruited into inflamed tissues partly via CCR2 
(Fadini et al., 2014) and the CCR2-CCL2 axis is one of the key regulatory pathways in 
macrophage migration (Izumi et al., 2013). In contrast, alternatively activated M2 
macrophages are characterized by their poor migratory capacity and key role in the resolution 
of the inflammatory response and regenerative repair in wound healing. Compatible with this 
notion, we found increased gene expression of CCR2 and CCL2 in M1 macrophages but 
decreased gene expression of CCR2 and CCL2 in M2 macrophages when compared to M0 
macrophages (Fig. 3A-B). Of note, MTP significantly decreased gene expression of CCR2 in 
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M0 macrophages treated with LPS and IFNγ to levels close to those observed in M2 
macrophages (Fig. 3A). These findings were in agreement with an MTP-induced reduction of 
cell motility during the treatment of M0 macrophages to be polarized into M1 macrophages, 
even when CCL2 was added (Fig. 3C).  
 
3.4. MTP prevents secretion of pro-inflammatory cytokines 
Next, we investigated the effect of MTP on macrophage activation by determining its ability 
to modulate pro-inflammatory cytokine production in response to LPS. M0 macrophages were 
exposed to LPS in the absence or presence of MTP for 24 h. MTP induced a decrease in the 
gene expression (Fig. 4A-C), and the protein expression (Fig. 4D-E) and secretion (Fig. 4F-H) 
of TNFα, IL-1β, and IL-6 in LPS-treated M0 macrophages.  
 
4. Discussion  
The uses of western therapies to treat inflammatory diseases are often suboptimal in terms of 
their associated side effects and cost. Currently, U. tomentosa is known as an herbal drug in 
several South American countries due to its beneficial effects on DNA repair and immune 
function (Sheng et al., 2000; Faria et al., 2012). Uncaria has proven to be a very valuable 
genus to the discovery and utilization of medicinal natural products that includes alkaloids. 
Therefore, the potential for development of leads from Uncaria needs to grow, particularly in 
the area of immunology, inflammation, and vascular-related disorders. The immunostimulant 
activity of pentacyclic oxindolic alkaloids (POA) from U. tomentosa may occur by increasing 
phagocytosis of granulocytes and macrophages, and by blocking the proliferation of myeloid 
cells (Keplinger et al., 1999). MTP is the most ubiquitous and abundant POA from U. 
tomentosa, and a recognised molecule with potent immunomodulatory and anti-inflammatory 
effects (Domingues et al., 2011). However, little is know about the mechanisms through 
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which those POA, and specifically MTP, are acting on the immune system and inflammatory 
pathways. 
One of the pivotal cells for the initiation of inflammation are monocytes, which exhibit 
different phenotypes according to the expression of the surface markers CD14 and CD16 
(Zawada et al., 2012). CD14 responses to bacterial LPS via toll-like receptor 4 (Hansson et 
al., 2011), whereas CD16 (FcγR-III) renders monocytes targets for activation by IgG-
containing immune complexes (IC) (Grivennikov et al., 2011). The majority of circulating 
monocytes belong to the classical monocytes CD14++CD16-; the remaining monocytes are 
described as the intermediate CD14++CD16+ and the non-classical CD14+CD16++ subsets 
(Zawada et al., 2011). The intermediate monocyte subset has a pro-inflammatory phenotype 
that actively produces TNFα (in response to LPS), IL-1β, IL-6, and leads to the progression of 
numerous inflammatory disorders such as atherosclerosis (Rogacev et al., 2014). It is 
necessary to maintain the proper balance among the different monocytes subsets for the 
appropriated inflammatory state. This study is the first to demonstrate that MTP may regulate 
the CD14/CD16 signature in human monocytes. MTP counteracted the imbalance of 
increased classical (CD14++CD16-) and intermediate (CD14++CD16+) monocytes, and 
decreased non-classical (CD14+CD16++) monocytes that induced LPS. This ability of MTP 
involved a decrease of CD14 expression and an increase of CD16 expression, resulting in a 
population of monocytes with lower classical and higher non-classical subsets. We also found 
that LPS-treated monocytes exposed to MTP were less migratory. Despite of the fact that 
CCR2 was less expressed in intermediate and non-classical monocytes in comparison with 
classical monocytes, MTP was shown to diminish CCR2 surface expression in all monocyte 
population but particularly in classical monocytes when co-treated with LPS. These findings 
could be explained due to the fact that CCR2 is not a static entity but is subjected to dynamic 
regulation in a time-dependent fashion by LPS (Heesen et al., 2006). 
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In response to inflammatory stimuli (i.e., LPS), the classical monocytes are selectively 
trafficked, in first instance, to the sites of inflammation, producing pro-inflammatory 
cytokines and contributing to local and systemic inflammation (Yang et al., 2014). These 
monocytes are highly infiltrative and can be differentiated into inflammatory macrophages, 
M1 acting in the acute phase of inflammation. In steady state, the non-classical patrolling 
monocytes patrol the vascular endothelium and become resident macrophages when they 
infiltrate into the inflamed tissue. During the late phase of inflammation, differentiated non-
classical monocytes (formally M2 macrophages) acquire an anti-inflammatory phenotype, 
which contribute to a shutdown of activated leukocytes and repair of damaged tissues 
(Murray et al., 2011). Sustained inflammation degenerates in chronic inflammatory diseases 
(Hotamisligil., 2006). Therefore, we decided to evaluate whether the shift from classical 
toward non-classical monocytes caused by MTP could lead to a different behaviour during 
polarization of macrophages derived from primary monocytes (M0 macrophages). It was 
exciting to observe that these macrophages, when treated with MTP, were hyporeactive to 
inducers (LPS and IFNγ) of M1 polarization and displayed a strong alternative activation as 
similarly occurred in response to the inducer (IL-4) of M2 polarization. Moreover, we found 
that M1 macrophages underwent a phenotypic regression toward M2 macrophages in the 
presence of MTP. These findings suggesting that MTP not only might have a potential role to 
reduce the M1/M2 macrophage ratio by an increased availability of non-classical monocytes, 
but also by interfering the polarization of M1 macrophages in a manner that is reminiscent of 
macrophage polarization to M2. In accordance with this notion, MTP dramatically reduced 
CCR2 expression and abolished the chemotactic capacity of macrophages during M1 
polarization. MTP also decreased the expression and secretion of several pro-inflammatory 
cytokines, which agreed with a previous study reporting, decreased plasma levels of TNFα, 
IL-1α, and IL-1β by oral administration of MTP in a murine model of LPS-induced 
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inflammation (Rojas-Duran et al., 2012). The additional effect of MTP to abolish nitric oxide 
production during macrophage polarization to M1 expands the current knowledge on 
antioxidant effects of other chemicals from Uncaria such as tannins and condensed tannins 
(Desmarchelier et al., 1997). Collectively, we showed for the first time that MTP, one of the 
major alkaloids of U. tomentosa, is able to immuno-modulate the phenotype and function of 
innate immune cells that are intimately involved in inflammation. Our results indicate 
unknown qualities of MTP, which are partly responsible for the anti-inflammatory activity of 
Uncaria´s extracts. These properties arise from its potency to switch pro-inflammatory state 
through immune system modulation, precisely, by skewing human monocytes to less 
inflammatory populations. Indeed, Uncaria´s extracts have been already shown to inhibit anti-
inflammatory responses via nuclear factor-kB (NF-kB), which regulates proinflamatory 
cytokines secretion (Aguilar et al.,2002). However, anti-inflamtory Uncaria´s activity is not 
solely due to MTP, certainly, the presence of this major alkaloid provides many of the anti-
inflammatory properties conferred on U. tomentosa. 
 
5. Conclusion 
In conclusion, we are the first to show that MTP might confer protection against 
inflammatory processes by skewing macrophage polarization to M2. This natural compound 
from U. tomentosa could be considered as a new player for therapy against inflammatory 
disorders. Nevertheless, further investigation must be conducted to approach this new 
therapeutic horizon. 
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Table 1. Sequences of qRT-PCR primers for gene expression analysis. 
Target 
GenBank 
accession number 
Direction Sequence (5’→3’) 
CD80 NM_005191.3 
Forward 
Reverse 
GGGAAAGTGTACGCCCTGTA 
GCTACTTCTGTGCCCACCAT 
CD200R NM_138940.2 
Forward 
Reverse 
GTTGCCCTCCTATCGCATTA 
TGGAAATTCCCATCAGGTGT 
MR NM_002438.3 
Forward 
Reverse 
GGCGGTGACCTCACAAGTAT 
ACGAAGCCATTTGGTAAACG 
CD64 NM_000566.3 
Forward 
Reverse 
GTCCAAATCTCCAAGTGCGG 
CCCAAGTATGAGAGCAGCGT 
CD163 NM_203416.3 
Forward 
Reverse 
TTGCCAGCAGCTTAAATGTG 
AGGACAGTGTTTGGGACTGG 
IL-1β NM_000576 
Forward 
Reverse 
GGGCCTCAAGGAAAAGAATC 
TTCTGCTTGAGAGGTGCTGA 
TNFα NM_000594                                                                                                                                                                                                                                                                                                                                                                        
Forward 
Reverse 
TCCTTCAGACACCCTCAACC 
AGGCCCCAGTTTGAATTCTT 
IL-6 NM_000600 
Forward 
Reverse 
TACCCCCAGGAGAAGATTCC 
TTTTCTGCCAGTGCCTCTTT 
IL-10 NM_000572 
Forward 
Reverse 
GCCTAACATGCTTCGAGATC 
TGATGTCTGGGTCTTGGTTC 
CCR2 NM_001123396.1 
Forward 
Reverse 
TGCCTGACTCACACTCAAGG 
GGCTTCTCAGCAACTGAACC 
MCP-1 NM_002982.3 Forward CCCCAGTCACCTGCTGTTAT 
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Reverse ACGAAGCCATTTGGTAAACG 
GAPDH NM_001289746 
Forward 
Reverse 
CACATGGCCTCCAAGGAGTA
AG 
CCAGCAGTGAGGGTCTCTCT 
β-Actin NM_001101 
Forward 
Reverse 
CGCAAAGACCTGTATGCCAA 
CACACAGAGTACTTGCGCTC 
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FIGURES LEGENDS 
 
Figure 1. (A) Apoptosis and necrosis representative pictures of flow cytometry analysis from 
human monocytes isolated from PBMCs (primary monocytes) after 24 h incubation with 
MTP (25 µM) or Staurosporine (1 µM). (B) FACS analysis of monocyte surface markers 
CD14 and CD16 after 24 h incubation with LPS (1 nM) in the absence or presence of MTP 
(25 µM). (C) CCR2 quantification and representative pictures of monocyte flow cytometry 
analysis after 24 h incubation with LPS (1 nM) in the absence or presence of MTP (25 µM). 
Values marked with different letters are significantly different (P < 0.05).  
 
Figure 2. (A) Mean fluorescence intensity (MFI) of CD68 in M0 macrophages obtained from 
primary monocytes. CD163 (B), CD64 (C), CD80 (D), CD200r (E), and MR (F) mRNA 
relative expression in M0, M1, and M2 macrophages. (G) Production of NO2- in M0 and M1 
macrophages. MTP (25 µM) was added to the medium for 24 h as indicated. Values marked 
with different letters are significantly different (P < 0.05).  
 
Figure 3. (A) CCR2, (B) CCL2 mRNA relative expression, and (C) migration index in M0, 
M1, and M2 macrophages. MTP (25 µM) and CCL2 (10 nM) were added to the medium for 
24 h as indicated. Values marked with different letters are significantly different (P < 0.01). 
 
Figure 4. (A) TNFα, (B) IL-1β, (C) IL-6 mRNA relative expression; (D) TNFα, (E) IL-1β 
densitometry analysis of immunoblotting detection; (F) TNFα, (G) IL-1β, and (H) IL-6 levels 
in the medium of M0 macrophages after 24 h incubation with LPS (1 nM) in the absence or 
presence of MTP (25 µM). Values marked with different letters are significantly different (P 
< 0.05). 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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